{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-043052","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-09-17T12:30:40+00:00","discovered_at":"2026-09-17T12:35:01.516859+00:00","generated_at":"2026-09-17T12:35:17.768145+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"bioAffinity Technologies wins Hong Kong patent for CyPath Lung lung cancer diagnostic","bullets":["Hong Kong IP Department granted Patent No. HK40048460 covering flow cytometry and fluorescent markers in sputum for lung cancer prediction.","Patent complements 2025 China patent; strengthens IP in Asia, which accounts for ~1.6M new lung cancer cases annually.","CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.","Company holds patents/pending in US, Australia, Canada, China, EU, Japan, Mexico, Singapore."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-043052","json":"https://secwatch.observer/filing/0001493152-26-043052.json","markdown":"https://secwatch.observer/filing/0001493152-26-043052.md","text":"https://secwatch.observer/filing/0001493152-26-043052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/0001493152-26-043052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-17T12:35:17.768145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}